Radiolabeled Peptide as Diagnostic, Therapeutic, and Theranostic agents for Prostate Cancer: Systematic Literature Review

Syabrina Salsabilah Gili, Muzakkir Baitz, Nurmaya Effendi

Abstract


Prostate cancer (PCa) is the most common sex-related malignancy and the second most common cause of mortality after lung cancer for men. Around 61.8% of Indonesian people undergo cancer treatment with surgery. This study aimed to figure out the use of radiolabeled peptides for diagnosis, therapy, and theranostics of prostate cancer. This study performed a literature review by searching the web databases such as PubMed, MDPI, Elsevier (Science Direct), and ACS Publications. The result showed that peptide compounds such RM2, VCN (Vicrostatin), DB15, and BBN7-14 were utilized as radionuclide-carriers for diagnostic imaging, meanwhile, peptides such as NeoBOMB1, PSMA-617, and [RGD-Glu-[DO3A]-6-Ahx-RM2] containing alpha or beta-emitted radionuclide were used as therapeutic and theranostic agents. They were tagged using 68Ga, 161Tb, 177Lu, 64Cu, 124I, 99mTc, 90Y, and 86Y radionuclides. Great efforts have been conducted in developing peptide-based radiopharmaceuticals for diagnosis and therapy of prostate cancer. Research groups focusing in nuclear medicine will continue to develop radiopharmaceuticals in the future, especially radiopeptide compounds for the diagnosis and therapy of prostate cancer.

Keywords


Radiolabelled-peptide; therapy; diagnosis; prostate cancer

Full Text:

PDF

References


Abouzayed A, Rinne S, Sabahnoo H, Sörensen J, Chernov V, Tolmachev V, Orlova A. Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS/SES-PEG2-RM26 for imaging of prostate cancer. Pharmaceutics. 2021; 13(2): 182.

Awaludin R. Menangani Kanker Dengan Radiopeptida. Buletin Alara. 2006; 8(2): 83-86.

Bandara N, Reynolds TJS, Schehr R, Bandari RP, Diebolder PJ, Krieger S, Xu J, Miao Y, Rogers BE, Smith CJ. Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist, [RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer. Nucl Med Biol. 2018; 62-62: 71-77.

Cheng S, Lang L, Wang Z, Jacobson O, Yung B, Zhu G, Gu D, Ma Y, Zhu X, Niu G, Chen X. Positron emission tomography ımaging of prostate cancer with Ga-68-labeled gastrin-releasing peptide receptor agonist BBN7-14 and antagonist RM26. Bioconjug Chem. 2018; 29(2): 410-419.

Dalm SU, Bakker IL, Blois ED, Doeswijk GN, Konijnenberg MW, Orlandi F, Barbato D, Tedesco M, Maina T, Nock BA, Jong MD. 68Ga/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017; 58(2): 293-299.

Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics. 2012; 2(5): 481–501.

Jadvar H, Chen K, Park R, Yap LP, Vorobyova I, Swenson S, Markland FS. Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer. Amino Acids. 2019; 51(10-12): 1569-1575.

Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, Oedegaard C, Saad A, Sandler I, Ben-Haim S, Domachevsky L, Berger R. A retrospective analysis of the safety and activity of lutetium-177-prostate-specific membrane antigen radionuclide treatment in older patients with metastatic castration-resistant prostate cancer. Oncologist. 2020;25(9):787-792.

Li X, Cai H, Wu X, Li L, Wu H, Tian R. New frontiers in molecular imaging using peptide-based radiopharmaceuticals for prostate cancer. Front Chem. 2020; 8: 583309.

Müller C, Umbricht CA, Gracheva N, Tschan VJ, Pellegrini G, Bernhardt P, Zeevaart JR, Köster U, Schibli R, Meulen NP. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2019; 46(9): 1919-1930.

Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, Jong MD, Maina T, Baum RP. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017; 58(1): 75-80.

Nock BA, Kaloudi A, Kanellopoulos P, Janota B, Bromińska B, Iżycki D, Mikołajczak R, Czepczynski R, Maina T. [99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes. Cancers (Basel). 2021; 13(20): 5093.

Pangribowo, S. Beban kanker di Indonesia. Pus. Data dan Inf. Kemeterian Kesehat. RI 1–16 2019

Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H. response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016 Sep;57(9):1334-8.

Rosilawati N, Nasution I, Murni T. Penggunaan radiofarmaka untuk diagnosa dan terapi di indonesia dan asas keamanan penggunaan obat. Soepra. 2018; 3(1), 60-73.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7-34.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer. Eur Urol Oncol. 2019; 2(2): 166-173.

Velikyan I. Radionuclides for imaging and therapy in oncology. In Cancer Theranostics; Chen, X., Wong, S., Eds.; Elsevier: Amsterdam, The Netherlands, 2014, pp. 285–325

Xia L, Wen L, Meng X, Zhou N, Guo X, Liu T, Xu X, Wang F, Zhu H, Yang Z. Application analysis of 124I-PPMN for enhanced retention in tumors of prostate cancer xenograft mice. Int J Nanomedicine. 2021; 16: 7685-7695.




DOI: https://doi.org/10.33096/pharmrep.v1i1.174

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy
Universitas Muslim Indonesia, Jl. Urip Sumohardjo KM 5 Kampus II, Makassar 90231, Indonesia
pharmaceutical.reports@umi.ac.id 

 Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Indexed By: